Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vital Images to use iCAD technology

This article was originally published in The Gray Sheet

Executive Summary

iCAD's Second Look CT computer-aided detection (CAD) will be integrated, pending FDA approval, into the firm's Vitrea 2 medical imaging software for diagnostic evaluation of CT and MR image data to detect polyps that could lead to colon cancer under a non-exclusive agreement. Vital Images inked a July deal with CAD-competitor R2 Technology to incorporate the latter firm's ImageChecker CT system with Vitrea 2 for lung nodules (1"The Gray Sheet" July 19, 2004, p. 22). Vital Images is a distributor for R2...

You may also be interested in...

R2 ImageChecker Approval Launches CAD Lung Market; iCAD Preps To Join

FDA approval of R2 Technology's ImageChecker CT CAD system for lung nodules July 8 provides the firm with a comfortable head-start over competitor iCAD, which expects to launch its own system in 2005

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts